TRANSBIO SUDOE aims at promoting interdisciplinary and interregional research in the field of health & life sciences.
TRANSBIO SUDOE can provide mobility support (transport & accommodation) for scientists interested in setting up collaborative research projects.
Below the procedure to launch a collaborative project :
Develop clinical trials for a new drug for dialysis patients
Request for technical support : - Need of TTO's support to ease collaboration agreements : No - Need for identification of funding opportunities (regional, national, European) : No
Added value of the cooperation : Share know-how / expertise
Summary of the proposal :
Develop clinical trials for a new drug for dialysis patients SNF472 till phase II.
Development of in-vivo and in-vitro assays. The first indication pursued for SNF472 is the treatment of calciphylaxis, a rare disease that affects between 1 and 4% of dialysis patients, with an average life expectancy of 1 year since his diagnosis. Calciphylaxis has its origin in the massive cardiovascular calcification of small peripheral blood vessels and there are currently no approved alternative treatments. Sanifit received orphan drug designation for SNF472 by the EMAandby the FDA.
Ricardo RODRIGUEZ, Galicia Anais GONZALEZ, Barcelona
CARE-U: take control of your health whichever you are